Twitter Facebook Google RSS
 
Global Defense 

Pentagon Opens Facility to Counter Biothreats 

2,017 

By Vivienne Machi 



The Defense Department is working with the biotech and pharmaceutical industry to run a state-of-the-art facility that can enable rapid development of key medical remedies tailored to military uses.

The medical countermeasure advanced development and manufacturing facility, recently opened in Alachua, Florida, will serve as a laboratory for pharmaceutical companies to bring in small teams to focus on counteragents for viruses, such as Ebola, and toxins that could be weaponized, such as anthrax. The facility’s development was overseen by the Joint Program Executive Office for Chemical and Biological Defense at Aberdeen Proving Ground, Maryland.

The 180,000 square-foot facility features two manufacturing suites with two rooms each that offer a flexible, modular space that can be used for a variety of needs, said Tim Belski, joint product director for advanced development manufacturing capabilities, and the government program manager for the effort.

The facility is rated at bio safety level III as specified by the Centers for Disease Control and Prevention, which means work can be done involving microbes that can cause serious and potentially lethal disease via inhalation, Belski said.

“That allows us to manufacture products that require a higher level of containment,” he said.

The Defense Department in 2013 awarded a contract to Nanotherapeutics, a private drug development company based in Alachua, to own and operate the building, while the U.S. government maintains ownership of the equipment, Belski said.

The facility cost approximately $205 million to develop, and became incrementally operational in August. It will be fully operational in February, though there are mechanisms in place to expand the current footprint and add three additional manufacturing suites if necessary, he said.

The facility could help the Defense Department entice more of the biotech industry to develop medical countermeasures in the chemical-biological threat area, which has traditionally been difficult, Belski noted.

Pharmaceutical companies “typically don’t see the return on investment in doing work with us to develop these medical countermeasures, because we don’t need very many,” he said.

This is the first facility of its kind to be established by the Defense Department, but Belski noted that the Department of Health and Human Services has a similar vehicle in place.

“They’ve done this to meet some of the more general population requirements, particularly for flu vaccines,” he said.

There is international interest in using the advanced development and manufacturing facility, Belski added.

Photo: Defense Dept.
Submit Your Reader's Comment Below
*Name
 
*eMail
 
The content of this field is kept private and will not be shown publicly.
*Comments
 
 
Refresh
Please enter the text displayed in the image.
The picture contains 6 characters.
*Characters
  
*Legal Notice

NDIA is not responsible for screening, policing, editing, or monitoring your or another user's postings and encourages all of its users to use reasonable discretion and caution in evaluating or reviewing any posting. Moreover, and except as provided below with respect to NDIA's right and ability to delete or remove a posting (or any part thereof), NDIA does not endorse, oppose, or edit any opinion or information provided by you or another user and does not make any representation with respect to, nor does it endorse the accuracy, completeness, timeliness, or reliability of any advice, opinion, statement, or other material displayed, uploaded, or distributed by you or any other user. Nevertheless, NDIA reserves the right to delete or take other action with respect to postings (or parts thereof) that NDIA believes in good faith violate this Legal Notice and/or are potentially harmful or unlawful. If you violate this Legal Notice, NDIA may, in its sole discretion, delete the unacceptable content from your posting, remove or delete the posting in its entirety, issue you a warning, and/or terminate your use of the NDIA site. Moreover, it is a policy of NDIA to take appropriate actions under the Digital Millennium Copyright Act and other applicable intellectual property laws. If you become aware of postings that violate these rules regarding acceptable behavior or content, you may contact NDIA at 703.522.1820.

 
 
  Bookmark and Share